Last reviewed: June 30, 2026
Last updated: June 30, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy (semaglutide) became one of the most prescribed weight loss medications after landmark clinical trials demonstrated 15-22% body weight reduction over 68 weeks. Determining who qualifies for this GLP-1 receptor agonist involves evaluating medical history, current health status, and weight loss goals rather than relying on a single number on the scale.
Standard Eligibility Requirements for Semaglutide Therapy
The foundational criteria for semaglutide eligibility include a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. Adults aged 18 and older who demonstrate motivation for lifestyle modification alongside pharmacotherapy are considered appropriate candidates. PlexusDx requires a telehealth consultation where a licensed clinician reviews your complete medical history before approving treatment.
Patients with a history of unsuccessful weight loss attempts through diet and exercise alone represent a significant portion of those who benefit from semaglutide injections. The medication works by activating GLP-1 receptors in the brain that regulate hunger signals and blood sugar control, making it effective for individuals whose weight gain stems from metabolic factors rather than behavioral choices alone. PlexusDx clinicians assess whether your specific situation aligns with evidence-based semaglutide use.
Medical Conditions That Impact Semaglutide Eligibility
Certain pre-existing conditions require careful evaluation before starting semaglutide injections. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 makes semaglutide contraindicated due to animal study findings showing thyroid C-cell tumors. Patients with active pancreatitis, severe gallbladder disease, or uncontrolled diabetic retinopathy may need to postpone treatment or explore alternative options. PlexusDx clinicians review imaging results, lab work, and medication lists to identify these barriers during your initial assessment.
Individuals with type 2 diabetes who take semaglutide often experience improved blood sugar control, which may require adjustments to existing diabetes medications. Those with a history of gastroparesis (slow stomach emptying) should inform PlexusDx clinicians, as GLP-1 medications can theoretically worsen this condition, though clinical experience shows most patients tolerate therapy well. Pregnancy and breastfeeding are absolute contraindications, and patients should plan accordingly if family planning is in their near-term goals.
Age and Kidney Function Considerations for Treatment Access
Semaglutide is approved for adults 18 years and older, with most clinical trial data collected in people aged 30-65. Younger adults in their 20s may qualify if they meet BMI and comorbidity thresholds, though clinicians often emphasize lifestyle intervention first in this group. Older adults (65+) can safely use semaglutide, but PlexusDx clinicians monitor kidney function more closely since dehydration from nausea could theoretically impact renal clearance in this population.
Kidney function testing (creatinine and estimated glomerular filtration rate) helps determine semaglutide safety, particularly for patients with stage 3-4 chronic kidney disease. The medication does not require dose adjustment for kidney disease, but dehydration prevention becomes important. PlexusDx requires baseline lab work or recent labs (within 6 months) to ensure treatment safety before your first semaglutide injection arrives.
How PlexusDx Personalizes Eligibility and Treatment Plans
Rather than applying a one-size-fits-all approach, PlexusDx uses telehealth clinician consultations and optional genetic testing to personalize your weight loss pathway. The Precision Peptide Genetic Test identifies variations in GLP-1 receptor sensitivity (GLP1R rs6923761), GIPR signaling (GIPR rs1800437), appetite regulation (FTO rs9939609), and metabolic pathways (MC4R rs17782313) that predict individual response to semaglutide therapy. This 14-pathway, 49-peptide analysis costs $99 as an add-on after your first month and helps clinicians fine-tune dosing strategy.
PlexusDx eligibility determination happens entirely through secure telehealth, with no insurance requirement and no membership fees. Compounded semaglutide injections start at $149 per month across all commitment tiers, with HSA and FSA eligibility available. If you meet standard medical criteria and have no absolute contraindications, PlexusDx can typically approve treatment within 24-48 hours, with your first shipment ready within days.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Does my BMI have to be exactly 30 to qualify for PlexusDx semaglutide?
No. PlexusDx clinicians consider BMI alongside weight-related conditions like diabetes, hypertension, or sleep apnea. A BMI of 27 with one qualifying condition, or BMI 30 without comorbidities, both represent valid starting points for eligibility discussion during your telehealth consultation.
What clinical evidence supports semaglutide for weight loss?
The STEP clinical trial program demonstrated that semaglutide 2.4 mg once weekly produced 15-22% body weight reduction versus 2-3% for placebo over 68 weeks. Participants also showed improvements in blood pressure, triglycerides, and fasting glucose, supporting both weight loss and metabolic health benefits.
Can I use PlexusDx compounded semaglutide if I have type 2 diabetes?
Yes. Semaglutide is particularly effective for those with diabetes and excess weight, often improving blood sugar control while reducing weight. However, PlexusDx clinicians may reduce your diabetes medication doses to prevent low blood sugar, making baseline medication review essential.
Are there serious side effects that would disqualify me from semaglutide?
History of medullary thyroid cancer or multiple endocrine neoplasia type 2 are absolute contraindications. Most other concerns (nausea, constipation, appetite changes) are manageable through dose titration. PlexusDx clinicians discuss risk versus benefit for each patient during consultation.
How does the Precision Peptide Genetic Test help determine my eligibility?
The test doesn't disqualify you but instead predicts your genetic predisposition to GLP-1 pathway sensitivity and metabolic traits. This information helps PlexusDx clinicians personalize starting doses and predict response, making treatment more precise from day one.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Give the Zepbound Injection: A Step-by-Step Guide
Understanding Ozempic: Is It for “Regular People”?